PT1848419E - Preparações injectáveis de diclofenaco e os seus sais farmaceuticamente aceitáveis - Google Patents
Preparações injectáveis de diclofenaco e os seus sais farmaceuticamente aceitáveis Download PDFInfo
- Publication number
- PT1848419E PT1848419E PT06745197T PT06745197T PT1848419E PT 1848419 E PT1848419 E PT 1848419E PT 06745197 T PT06745197 T PT 06745197T PT 06745197 T PT06745197 T PT 06745197T PT 1848419 E PT1848419 E PT 1848419E
- Authority
- PT
- Portugal
- Prior art keywords
- diclofenac
- preparations
- pharmaceutically acceptable
- acceptable salts
- high concentration
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 56
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title claims description 47
- 229960001259 diclofenac Drugs 0.000 title claims description 31
- 150000003839 salts Chemical class 0.000 title claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 60
- 239000002904 solvent Substances 0.000 claims description 44
- 239000006184 cosolvent Substances 0.000 claims description 40
- 238000002347 injection Methods 0.000 claims description 37
- 239000007924 injection Substances 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 21
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 229960001193 diclofenac sodium Drugs 0.000 claims description 10
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 239000011261 inert gas Substances 0.000 claims description 10
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical group [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 10
- 150000005846 sugar alcohols Polymers 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 239000008227 sterile water for injection Substances 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- -1 alkali metal salt Chemical class 0.000 claims description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 4
- 238000011146 sterile filtration Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940102223 injectable solution Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 2
- 208000014677 Periarticular disease Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims description 2
- 229940057847 polyethylene glycol 600 Drugs 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000011477 surgical intervention Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 4
- 235000006708 antioxidants Nutrition 0.000 claims 4
- 101000926072 Varicella-zoster virus (strain Dumas) Envelope glycoprotein C Proteins 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 230000037396 body weight Effects 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004064 cosurfactant Substances 0.000 description 4
- 210000000852 deltoid muscle Anatomy 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 231100000064 subacute toxicity study Toxicity 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- ZQVZPANTCLRASL-UHFFFAOYSA-N 2-[2-(2,6-dichloroanilino)phenyl]acetate;diethylazanium Chemical compound CCNCC.OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl ZQVZPANTCLRASL-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN96MU2005 | 2005-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1848419E true PT1848419E (pt) | 2012-10-31 |
Family
ID=36953757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06745197T PT1848419E (pt) | 2005-02-01 | 2006-01-30 | Preparações injectáveis de diclofenaco e os seus sais farmaceuticamente aceitáveis |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8809393B2 (enExample) |
| EP (1) | EP1848419B1 (enExample) |
| JP (1) | JP2008528572A (enExample) |
| KR (1) | KR101226121B1 (enExample) |
| CN (1) | CN101123957B (enExample) |
| AP (1) | AP2888A (enExample) |
| AU (2) | AU2006221633B2 (enExample) |
| BR (1) | BRPI0606119B8 (enExample) |
| CA (1) | CA2596031C (enExample) |
| DK (1) | DK1848419T3 (enExample) |
| EA (1) | EA013616B1 (enExample) |
| ES (1) | ES2392097T3 (enExample) |
| IL (1) | IL184697A (enExample) |
| MX (1) | MX2007009312A (enExample) |
| NZ (1) | NZ554779A (enExample) |
| PL (1) | PL1848419T3 (enExample) |
| PT (1) | PT1848419E (enExample) |
| UA (1) | UA93365C2 (enExample) |
| WO (1) | WO2006095363A2 (enExample) |
| ZA (1) | ZA200705729B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009155315A (ja) * | 2007-12-26 | 2009-07-16 | Fujiyakuhin Co Ltd | 注射剤 |
| WO2013005226A1 (en) * | 2011-07-04 | 2013-01-10 | Zota Health Care Ltd | A novel combined pharmaceutical composition containing diclofenac and methods of making and using the same |
| US20140187635A1 (en) | 2012-12-28 | 2014-07-03 | Themis Medicare Limited | Diclofenac compositions |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| CN103432132B (zh) * | 2013-08-31 | 2015-01-21 | 西南大学 | 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法 |
| WO2016170401A1 (en) * | 2015-04-20 | 2016-10-27 | Umedica Laboratories Pvt. Ltd | Novel injectable composition of diclofenac sodium |
| US20220280463A1 (en) | 2019-09-09 | 2022-09-08 | Ftf Pharma Private Limited | Pharmaceutical formulations comprising diclofenac |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8200488L (sv) | 1982-01-29 | 1983-07-30 | Svenska Flaektfabriken Ab | Arreteringsanordning, serskilt for forankring av till- och franluftventiler i ventilationskanaler |
| DE3328401A1 (de) * | 1983-08-05 | 1985-02-21 | Merckle GmbH, 7902 Blaubeuren | Injizierbare loesung zur behandlung von entzuendungen |
| DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| DE3613799C1 (de) * | 1986-04-24 | 1987-09-03 | Nattermann A & Cie | Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln |
| ATE164080T1 (de) * | 1990-05-10 | 1998-04-15 | Bechgaard Int Res | Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole |
| US5389681A (en) * | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| US5554650A (en) * | 1994-07-28 | 1996-09-10 | Southern Research Institute | Antiphlogistic, analgesic, antipyretic injection preparation |
| GB9502695D0 (en) | 1995-02-11 | 1995-03-29 | Glaxo Spa | Pharmaceutical composition |
| US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| WO1997049411A1 (en) * | 1996-06-25 | 1997-12-31 | Glaxo Group Limited | Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv |
| US5853263A (en) * | 1996-08-15 | 1998-12-29 | Accrued, Inc. | System for installing raised road markers |
| US6846495B2 (en) * | 1999-01-11 | 2005-01-25 | The Procter & Gamble Company | Compositions having improved delivery of actives |
| DE10105576C1 (de) * | 2001-02-07 | 2002-08-08 | Underberg Kg | Flasche mit im Boden ausgebildeten Griffmulden |
| IN192711B (enExample) | 2002-01-22 | 2004-05-15 | Ketan Rajnibhai Patel | |
| CH694034A8 (de) * | 2002-12-12 | 2004-08-31 | Mepha Ag | Diclofenac-Kalium-Injektionsloesung. |
| EP1605916A4 (en) * | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | SOLVENT SYSTEM OF A SMOOTH MEDICAMENT WITH IMPROVED ELUTION RATE |
| KR100612070B1 (ko) * | 2003-02-12 | 2006-08-11 | 알앤피코리아주식회사 | 용출률이 향상된 난용성 약제의 용매 시스템 및 이를 함유한 제약학적 제제 |
| CN1557290A (zh) | 2004-01-19 | 2004-12-29 | 江苏扬子江药业集团有限公司 | 复方双氯芬酸钾注射液制剂 |
| AU2004317520B2 (en) | 2004-03-10 | 2011-06-09 | Shimoda Biotech (Pty) Ltd | Stable injectable diclofenac compositions |
| CN1279897C (zh) | 2004-04-30 | 2006-10-18 | 济南百诺医药科技开发有限公司 | 含有双氯芬酸盐和利多卡因的冻干制剂及其制备方法 |
| ITMI20041245A1 (it) | 2004-06-22 | 2004-09-22 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
-
2006
- 2006-01-30 WO PCT/IN2006/000033 patent/WO2006095363A2/en not_active Ceased
- 2006-01-30 EA EA200701645A patent/EA013616B1/ru not_active IP Right Cessation
- 2006-01-30 KR KR1020077019888A patent/KR101226121B1/ko not_active Expired - Fee Related
- 2006-01-30 JP JP2007552812A patent/JP2008528572A/ja active Pending
- 2006-01-30 PL PL06745197T patent/PL1848419T3/pl unknown
- 2006-01-30 ES ES06745197T patent/ES2392097T3/es not_active Expired - Lifetime
- 2006-01-30 AP AP2007004101A patent/AP2888A/xx active
- 2006-01-30 BR BRPI0606119A patent/BRPI0606119B8/pt not_active IP Right Cessation
- 2006-01-30 NZ NZ554779A patent/NZ554779A/en not_active IP Right Cessation
- 2006-01-30 UA UAA200708877A patent/UA93365C2/ru unknown
- 2006-01-30 US US11/883,331 patent/US8809393B2/en active Active
- 2006-01-30 MX MX2007009312A patent/MX2007009312A/es active IP Right Grant
- 2006-01-30 AU AU2006221633A patent/AU2006221633B2/en not_active Ceased
- 2006-01-30 PT PT06745197T patent/PT1848419E/pt unknown
- 2006-01-30 DK DK06745197.1T patent/DK1848419T3/da active
- 2006-01-30 CA CA2596031A patent/CA2596031C/en not_active Expired - Lifetime
- 2006-01-30 CN CN2006800034355A patent/CN101123957B/zh not_active Expired - Fee Related
- 2006-01-30 EP EP06745197A patent/EP1848419B1/en not_active Expired - Lifetime
-
2007
- 2007-07-12 ZA ZA200705729A patent/ZA200705729B/xx unknown
- 2007-07-18 IL IL184697A patent/IL184697A/en not_active IP Right Cessation
-
2009
- 2009-10-29 AU AU2009233594A patent/AU2009233594A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20080153914A1 (en) | 2008-06-26 |
| BRPI0606119B8 (pt) | 2021-05-25 |
| NZ554779A (en) | 2011-02-25 |
| KR101226121B1 (ko) | 2013-01-25 |
| DK1848419T3 (da) | 2012-11-05 |
| PL1848419T3 (pl) | 2012-12-31 |
| BRPI0606119A2 (pt) | 2009-06-02 |
| CA2596031A1 (en) | 2006-09-14 |
| EP1848419B1 (en) | 2012-07-25 |
| CN101123957A (zh) | 2008-02-13 |
| MX2007009312A (es) | 2008-03-10 |
| UA93365C2 (ru) | 2011-02-10 |
| AU2009233594A1 (en) | 2009-11-19 |
| WO2006095363A2 (en) | 2006-09-14 |
| ES2392097T3 (es) | 2012-12-04 |
| IL184697A0 (en) | 2007-12-03 |
| CA2596031C (en) | 2013-02-19 |
| CN101123957B (zh) | 2010-12-08 |
| WO2006095363A3 (en) | 2006-12-14 |
| EA200701645A1 (ru) | 2008-02-28 |
| KR20070107091A (ko) | 2007-11-06 |
| AU2006221633B2 (en) | 2009-07-30 |
| JP2008528572A (ja) | 2008-07-31 |
| EA013616B1 (ru) | 2010-06-30 |
| IL184697A (en) | 2014-02-27 |
| US8809393B2 (en) | 2014-08-19 |
| AP2007004101A0 (en) | 2007-08-31 |
| EP1848419A2 (en) | 2007-10-31 |
| WO2006095363B1 (en) | 2007-02-01 |
| BRPI0606119B1 (pt) | 2019-05-07 |
| AU2006221633A1 (en) | 2006-09-14 |
| ZA200705729B (en) | 2008-08-27 |
| AP2888A (en) | 2014-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2784629T3 (es) | Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona | |
| ES2711760T3 (es) | Emulsiones de aceite/agua que comprenden alcanos semifluorados | |
| AU2013368849B2 (en) | Diclofenac composition | |
| ES2843723T3 (es) | Formulaciones farmacéuticas inyectables de lefamulina | |
| AU2009233594A1 (en) | Injectable preparations of diclofenac and its pharmaceutically acceptable salts | |
| US9211251B2 (en) | Injectable preparations of diclofenac and its pharmaceutically acceptable salts | |
| ES2215856T3 (es) | Solucion de sal monosodica tetrahidrato de n-(o-(p-pivaloiloxibenceno-sulfonilamino)benzoil)glicina y medicamento que contiene esta solucion. | |
| WO2016170401A1 (en) | Novel injectable composition of diclofenac sodium | |
| ES2794093T3 (es) | Formulación parenteral de esmolol | |
| RU2008126108A (ru) | Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту | |
| RU2290922C1 (ru) | Средство для лечения болезней суставов | |
| RU2292203C1 (ru) | Средство для лечения болезней суставов | |
| BRPI0902144A2 (pt) | processo para preparar uma composição farmacêutica sólida, de administração por via oral que contém os prìncipios ativos glicosamina e meloxicam e uso da associação entre glicosamina e meloxicam |